Betibeglogene autotemcel
From WikiMD's WELLNESSPEDIA
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a medication for the treatment for beta thalassemia. It was developed by Bluebird Bio and was given breakthrough therapy designation by the U.S. Food and drug Administration in February 2015. It was approved for medical use in the European Union in May 2019. The most serious side effect observed is thrombocytopenia (low blood levels of platelets).
| This article is a stub. You can help WikiMD by registering to expand it. |
